In short
Medical research studies continued. This month's update did not focus on Parkinson's research.
July's update was the shortest of the year, and most of it covered other topics.
On the research, it said Zhittya's medical research studies were continuing and that nothing had slowed down. Participants were still being dosed and still reporting back. The chief executive wrote that what they were telling the team continued to encourage him, and that participants were still reporting improvement.
This summary covers the Parkinson's research in the July 2026 update. The complete update, including the other topics it covered, is below.
Read the complete July 2026 update as published
The text of the update Zhittya sent, word for word. Pictures, charts and layout are in the PDF. Open the PDF.
July 17, 2026 Monthly Update
A Short Zhittya Update This Month
This will be the shortest Monthly Update I have ever written.
Zhittya Is Continuing To Do Well
Our medical research studies are progressing. Our patients are reporting back to us, and what they are telling us continues to encourage me. Our events over the last 30 days went well, better than I expected in some cases, and we met people who I believe will matter to this company for years to come. We Are 100% Focused on the WUND Healing Bio Common Stock Offering
WUND Healing Biopharmaceuticals is pursuing a public listing through an SEC Regulation A offering. The offering is being conducted through Benjamin Securities, and everything you need to know about it is in one place: https://www.benjaminsecurities.com/wund-offering
That link is all I want in front of you this month.
When a company is in SEC registration, there are rules about what management can say and when it can say it. Those rules exist so that everyone gets the same information at the same time, in the same document, reviewed by the same regulators. I understand the rules and the logic, and we are following those rules to the letter.
So, the entire Zhittya team is focused on this WUND common stock offering.
Who WUND Wants in This Offering
WUND is offering 1,000,000 shares of common stock at $10.00 per share.
WUND wants as many small investors as possible.
WUND and Benjamin Securities worked through the structure of this common stock offering together, and they came to an agreement that small investments of $5,000 will get priority.
An indication for 500 shares at $10.00 per share. A $5,000 investment will be first in line.
How to Learn More
If you are interested in the WUND stock offering, everything you need is in the offering circular. That is the document that governs, and it is the only document that governs. Please read it, including the risk factors, because this is an investment, and investments carry risk. Read it before you make any decisions.
To review the offering materials and the offering circular, go to: https://www.benjaminsecurities.com/wund-offering Everything Else for Zhittya Continues on Course.
Our medical research studies are continuing. Our patients are still being dosed, still reporting, still improving. Cross-Border is still filling cohorts. Sam Cross is still taking calls at 714-393-8605 and sam.crossbordermedical@gmail.com if you or someone you love wants to be considered.
Nothing has slowed down at Zhittya. The only thing that has changed is what I am allowed to write to you about this month.
Conclusion by Dan Montano
I turned 78 this month.
I have been at this for 28 years. I believe FGF-1 is a major medical breakthrough.
WUND and Benjamin Securities opened that door at $5,000 for small investors.
The next 30–60 days I believe are important to our overall success.
I am blessed, and I pray that you are also blessed.
God bless you, and thank you all.
Dan Montano
CEO, Zhittya Genesis Medicine
8683 W. Sahara Ave., Suite 280
Las Vegas, NV 89117 (USA)
702-802-8373 zgm.care
<https://www.benjaminsecurities.com/wund-offering>
<https://www.benjaminsecurities.com/wund-offering>
[mailto:Sam.crossbordermedical@gmail.com](mailto:Sam.crossbordermedical@gmail.com)